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1. Introduction
Osteoporosis is a systemic disease that is characterized by low bone mass and deterioration of
the microarchitecture of bone, resulting in an increased risk of fracture in postmenopausal
women and men over 50 years old. Several factors have been identified that contribute to the
risk of osteoporosis, and oxidative stress has now emerged as one of the most important life
style risk factor associated with loss of bone mass. Phytochemicals as antioxidants have been
shown to counteract the deleterious effects of oxidative stress in the risk of osteoporosis. This
review will include an overview on osteoporosis, the deleterious effects of oxidative stress and
the beneficial effects of phytochemical antioxidants, with emphasis on the results of our clinical
studies on the phytochemical lycopene and polyphenols present in nutritional supplements.
2. Osteoporosis – An overview
Osteoporosis is a metabolic bone disease known as “the silent thief” because the gradual loss
of bone associated with this disease usually occurs over the years, and there are usually no
noticeable symptoms until the bones are so fragile that a fracture occurs [1]. Osteoporosis is
“a major public health threat” that is projected to results to 8.1 million fractures (78 % women,
22 % men) during the period between 2010 and 2050 [2]. Approximately 1 in 2 women and 1
in 5 men older than 50 years will eventually experience osteoporotic fractures [3]. The condition
costs our healthcare system $18 billion per year [4]. Newer findings on all aspects of osteopo‐
rosis have increased exponentially. The more importantly ones are discovering an ever
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increasing number of risk factors including oxidative stress, opening up new knowledge on
the involvement of the bone forming cells osteoblasts and the bone resorbing cells osteoclasts
in the development of osteoporosis, the introduction and improvement of more sensitive
diagnostic instruments, and finding new drugs and the nutritional alternatives for the
prevention and treatment of osteoporosis. Advances in the knowledge on osteoporosis is not
without pitfalls. Hormone Replacement Therapy (HRT), once a first line of treatment for
osteoporosis has been discontinued due to side effects [5]. It is becoming more evident that the
drugs known as bisphosphonates, although effective in stopping the resoption of bone and
preventing osteoporosis in women, are associated with a number of side effects [6, 7]. Because
of this, a number of women are now resorting to other modes of treatment, including that from
natural food components. Our laboratory has carried out studies on the use of phytochemical
antioxidants such as lycopene and polyphenols present in nutritional supplements as possible
alternatives and/or complementary to drugs in the treatment and prevention of osteoporosis.
This chapter will include an overview on osteoporosis, oxidative stress as a risk factor in the
development of osteoporosis and a review of studies on the use of antioxidants in counteract‐
ing oxidative stress in the prevention of osteoporosis. These topics should put our research in
perspective and offer a rationale to our study approaches. Finally we will highlight our
pioneering clinical studies on the lipid-soluble phytochemical antioxidant lycopene and the
water-soluble antioxidant polyphenols present in a nutritional supplement in the prevention
of risk for osteoporosis in postmenopausal women.
2.1. Risk factors for osteoporosis
Some of the risk factors for osteoporosis [8, 9] are presented in Table 1 [10]. The risk factors
that are of interest in our studies are the oxidative stress-generating factors, including nutrition
deficiency, low antioxidant status, smoking, alcohol intake, excessive sports activity and
caffeine intake.
Unmodifiable Modifiable
Race
Sex
Age
Genetics
Body size
Family History
Previous Fractures
Chronic inactivity
Low body weight
Low lifetime calcium intake
Medication used
Oxidative stress-related
Factors:
Smoking
High Alcohol intake
Low antioxidant status
Nutrition deficiency
Excessive sports activity
Excessive caffeine intake
Table 1. Risk Factors for Osteoporosis
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2.2. Prevention and treatment of osteoporosis
Until 10 years ago, the first line of treatment for women who have gone through menopause
and were diagnosed with osteoporosis was hormone replacement therapy (HRT). However,
results of the Women’s Health Initiative (WHI) revealed that women taking HRT had higher
risks for breast cancer, cardiovascular events, blood clots, cognitive decline, and more [5]. This
treatment for osteoporosis has since been discontinued and is prescribed only for a short period
of time to alleviate hot flashes in menopausal women [11]. The current treatments which inhibit
bone resorption that are approved by the Food and Drug Administration (FDA) include a
number of bisphosphonates under specific trademarks [12]. Some are taken daily while others
are formulated for weekly, monthly or intermittent oral use [13, 14]. The newer bisphophonates
are injectables such as Zoledronate and Ibandronate [14]. Other drugs available include
calcitonin; Raloxifene (Evista), the Selective Estrogen Receptor Modulator (SERM) and
strontium renalate [15]. Parathyroid hormone, PTH1-34 or teriparatide (Forteo), is the only
anabolic agent currently approved for use by the FDA [16, 17]. The new class of osteoporosis
drug now approved for use is a human monoclonal antibody (Denosumab) which bind to
RANKL, imitating the effects of OPG and acting as an inhibitor of RANKL [18]. Other drugs
are still being tested clinically for osteoporotic treatment and prevention [16].
None of the drugs are without side effects. Side effects that emerged in clinical trials include
acute phase response with iv treatment or high-dose oral therapy and esophageal irritation
with oral administration. Osteonecrosis of the jaw, musculoskeletal complaints, and atypical
fractures are some uncommon side effects that have been noted with wide clinical use of
bisphosphonate. The number of these events are small, and a clear cause-and-effect relation‐
ship between events and bisphosphonate treatment has not been established. Accumulation
of Bisphosphonates in the bone create a reservoir leading to continued release from bone for
months or years and provide some residual anti-fracture reduction long after treatment is
stopped [19]. As a result, there is a recommendation for a drug holiday after 5 –10 yr of
treatment with bisphosphonate [7, 19]. The length of the holiday is based on previous duration
of treatment, BMD status and fracture risk. Studies with alendronate and risedronate showed
that if treatment is stopped after 3–5 yr, there is at least 1–2 yr persisting anti-fracture efficacy.
The consensus from expert panels [7] for those who are not on holiday is not to stop the use
of drug since the side effects are often rare, and that the benefits outweigh the side effects. In
the balance, most individuals who have osteoporosis are much better taking an osteoporosis
medication [6].
2.3. Alternative approach to prevention and treatment of osteoporosis
Diet is now recognized as an important life-style factor in the management of bone health [20].
Given that many nutrients have been identified as being beneficial to bone health [21, 22], there
is strong scientific support for the potential benefits of incorporating therapeutic nutritional
interventions with contemporary pharmaceutical treatments [23]. As a result of the possible
adverse side effects of HRT [5] and the ever increasing reports on the side effects of bisphosph‐
onates that are prescribed for the management of postmenopausal osteoporosis [19], comple‐
mentary and alternative medicine (CAM) is in demand as an alternative for the prevention
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and treatment of osteoporosis [24]. CAM is the term for medical practices, services and
products that are not a part of standard care. Some of the approaches include exercise,
acupuncture, diet, herbs rich in polyphenols and nutritional supplements including calcium,
zinc, magnesium boron and other vitamins and minerals [24]. Recent dietary guidelines for
the prevention of chronic diseases have recommended an increase in the consumption of fruits
and vegetables worldwide [25] that are good sources of dietary antioxidants [26]. The beneficial
effects of antioxidants in bone health and osteoporosis are demonstrated epidemiologically
and through clinical intervention. As will be reviewed in this chapter, our clinical studies on
lycopene treatment and nutritional supplements containing polyphenols and other nutritional
components showed positive results on bone health.
3. Oxidative stress and antioxidants – An overview
Oxidative stress is caused by reactive oxygen species (ROS) which are the main by-products
formed in the cells of aerobic organisms that can initiate autocatalytic reactions in such a way
that the target molecules get converted into free radicals causing a chain of damage [27]. There
is ample evidence to show that oxidative stress induces an increase in the rate of bone loss and
is therefore a risk factor for osteoporosis. Epidemiological evidence in humans and studies in
animals indicate that aging and the associated increase in reactive oxygen species (ROS) are
responsible for bone loss [28]. Oxidative stress is associated with the activity and function of
both the osteoblasts and osteoclasts cells, the two major bone cells involved in the pathogenesis
of osteoporosis [29, 30].
Under normal physiological conditions, the cells can fight free radical attack or oxidative stress
by promoting antioxidant defenses. A number of endogenous defense mechanisms are present
in the body, including the metal chelating proteins and the endogenous antioxidant enzymes
superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) [31]. Exoge‐
nous antioxidants come from dietary sources present in fruits and vegetables containing
several phytonutrient antioxidants two of which are the potent antioxidant lipid-soluble
lycopene and the water-soluble antioxidant polyphenols [32]. In cases where the exogenous
antioxidants or antioxidants from diet fail to prevent oxidative damage, the repair antioxidants
come into play which include DNA repair enzymes, protease, lipase, and transferase [33].
When antioxidants loses its fight with oxidative stress, diseases associated with oxidative stress
develop, which include cardiovascular disease, cancer, diabetes, neurological diseases and
osteoporosis [26].
3.1. Lycopene, a lipid-soluble phytochemical antioxidant
The role of lycopene in the prevention of human diseases is supported by a number of evidence
and previously reviewed [34, 35]. Since then, there have been several epidemiological as well
as clinical intervention studies showing the relationship between lycopene intake and the
prevention of cancers at other sites, as well as coronary heart disease, diabetes, hypertension,
macular degenerative disease, neurodegenerative disease and male infertility [26]. The role of
Phytochemicals - Isolation, Characterisation and Role in Human Health250
lycopene in bone health has so far been based on its potent antioxidant properties, the well-
known role of oxidative stress in bone health, the limited studies on the effects of lycopene in
bone cells in culture [34, 35] and the results of epidemiological studies [36, 37]. To date our
clinical intervention studies at St. Michael’s Hospital on the role of lycopene and elucidation
of its mechanism in lowering the risk for osteoporosis in postmenopausal women (aged 50 to
60 years) are so far the only clinical studies reported in the literature.
3.2. Polyphenols, the water-soluble antioxidant
Polyphenols are a class of water-soluble molecules naturally found in plants [38]. It is estimated
that there are 10,000 different phytonutrients (phyto, meaning from plants). The health benefits
associated with fruits, vegetables, tea, red wine, and Mediterranean diets are probably linked
to the polyphenol antioxidants [21, 39, 40]. The polyphenols of interest in our study are a
mixture of flavonoids such as quercetin, apigenin, kaempferol and luteolin present in the
supplement greens+TM [41]. greens+TM in combination with another supplement, bone build‐
erTM, were used in our study on osteoblasts cells and in clinical intervention studies on the
prevention of risk of osteoporosis in postmenopausal women as will be reviewed below.
4. Studies on the antioxidants polyphenols and lycopene
4.1. Studies on lycopene
The direct role of lycopene in osteoblasts and osteoclasts, the cells involved in the pathogenesis
of osteoporosis, is now being unraveled. This involvement is further supported by both
epidemiological and clinical intervention with lycopene in postmenopausal women who are
at risk of osteoporosis [29, 30].
An epidemiological study to determine the beneficial role of lycopene in the prevention of risk
for osteoporosis was carried out by Rao et al [36]. In a cross-sectional study, 33 postmenopausal
women aged 50–60 years participants were recruited and asked to provide seven-day dietary
records and blood samples for analyses of total antioxidant capacity; oxidative stress param‐
eters including lipid peroxidation and protein oxidation; and bone turnover markers including
bone resorption marker NTX and bone formation marker. Their results showed that the
estimated dietary lycopene had a significant and direct correlation with serum lycopene,
suggesting that lycopene from the diet is bioavailable. Their conclusion that the higher serum
lycopene was associated with a low NTx (p<0.005) and lower protein oxidation (p<0.05)
supports the antioxidative properties of lycopene involvement in its mechanisms of action in
bone [36].
The overall conclusions that can be derived from the cross-sectional study is that lycopene has
a role in the prevention of risk for osteoporosis. Further clinical studies described below
support this conclusion.
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Mackinnon et al [42] studied whether the elevated dose obtained through lycopene supple‐
mentation compared to intakes typically obtained from the usual daily diet was more beneficial
in reducing bone turnover markers. Serum lycopene, bone turnover markers and oxidative
stress parameter data were compared between postmenopausal women who were supple‐
mented with lycopene and those who obtained both a low and high intake lycopene from daily
food diet. Results showed that women who consumed lycopene supplement had significantly
lower TBARS values than participants who obtained a low intake or high intake lycopene
through their usual daily diets. These differences in TBARS value may be attributed to a
significantly higher concentration of serum 5-cis in lycopene-supplemented participants
compared to participants who obtained their lycopene from low or high usual daily diet. This
suggests that it is the 5-cis isomer, with the most potent antioxidant capacity which, at higher
concentrations, decreases bone turnover markers due to its ability to provide the greatest
protection against oxidative stress. It also appears to show that supplementation with lycopene
may be necessary in spite of the daily intake of lycopene [42].
Another study was carried out to determine the effects of a lycopene-restricted diet on
oxidative stress parameters and bone turnover markers in postmenopausal women [43].
Results showed that restricting the participants from consuming lycopene-containing prod‐
ucts resulted in significant decreases in serum lycopene, α-/β-carotene and lutein/zeaxanthin,
with the overall change in the serum carotenoids being lower than that seen for lycopene. All
configurations of lycopene (all trans, 5-cis- and other cis lycopene) were found to be decreased
and the antioxidant enzymes SOD and CAT were also significantly depressed after lycopene
restriction. These changes were accompanied by a significant increase in the bone resorption
marker NTx. The important conclusion from this study is the possibility that the significant
increase in the bone resorption marker NTx could lead to a long-term decrease in BMD and
increased fracture risk as was observed by Brown et al. [44]; longer restriction period may be
detrimental to a group of postmenopausal women who were already at high risk for osteo‐
porosis. Therefore, shorter wash-out periods of no lycopene consumption is all that is needed
in clinical trials examining the effects of lycopene on bone health [43].
A clinical fully randomized controlled intervention study was next carried out by Mackin‐
non et al [45] to investigate directly the effects of lycopene supplementation on decreas‐
ing the risk for osteoporosis. Lycopene supplements include lycopene capsules, tomato juice
with normal amount of lycopene, tomato juice with high amount of lycopene. They have
shown  that  after  the  4-month  duration,  the  LYCOPENE-supplemented  group  had  a
significant  increase in  total  antioxidant  capacity,  decrease in  oxidative stress  parameters
protein oxidation as shown by increase in thiol values and lipid peroxidation as shown by
TBARS which correlated to a decrease in NTx; all changes were significantly different from
the PLACEBO group. These findings suggest that lycopene obtained in the form of tomato
juice or capsule exerted equivalent antioxidant potency in reducing the risk of osteoporo‐
sis in postmenopausal women [45].
Mackinnon et al studied whether polymorphism plays a role in the development of osteopo‐
rosis [46]. To do this, Mackinnon et al. studied the role of 172T→A or 584A→G polymorphisms
Phytochemicals - Isolation, Characterisation and Role in Human Health252
of the paraoxonase 1 (PON 1) in modulating the effects of serum lycopene on antioxidant
capacity, oxidative stress parameters and bone turnover markers, and in women between the
ages of 25-70 years). Their results showed that the PON1 polymorphism modified the associ‐
ation between lycopene and NTx and BAP, an interaction that may also moderate the risk of
osteoporosis [46].
In another study, they showed that there was a significant interaction between PON1 genotype
and change in TBARS (p<0.05) suggesting that supplementation with lycopene resulted in
decreased lipid peroxidation, which interacted with the PON1 genotype to decrease bone
resorption markers in postmenopausal women. These results provided a mechanistic evidence
of how intervention with lycopene may act to decrease lipid peroxidation and thus the risk of
osteoporosis in postmenopausal women [45, 47].
In conclusion, the demand for the use of other natural food components in the management
of postmenopausal osteoporosis has increased due to reports on the adverse side effects of the
conventional therapy (eg, HRT and bisphosphonates). The studies reviewed above revealed
evidence that antioxidants such as lycopene can counteract the damaging effects of oxidative
stress brought about by ROS that lead to the development of osteoporosis. The results of studies
reviewed here indicate that lycopene maybe useful either as a dietary alternative to drug
therapy or as a complement to the drugs presently approved for used by women at risk of
osteoporosis.
4.2. Studies on polyphenols
It is well known that polyphenols have a role in the prevention of chronic diseases such as
cancers, diabetes, cardiovascular diseases, neurodegenerative diseases, and osteoporosis.
Interest on polyphenols and bone health has increased in the last 10 years [48-51]. The anabolic
role of phytonutrients and especially polyphenols in bone was reviewed by Horcajada [49],
the mechanisms of action of polyphenol in osteoblast function and its interaction with
osteoclasts was reviewed by Trzeciakiewicz [50] and the beneficial effects of green tea
polyphenols has been reviewed [52, 53].
Currently, most of the research on polyphenols and their effects have emerged from in vitro
and in vivo animal studies with only a few clinical studies available. In our recent review, we
have included tables listing all the studies on polyphenols in vitro bone cell culture and the
epidemiologic studies on the protective effects of polyphenol consumption against osteopo‐
rosis [54].
Combinations of polyphenols have also been studied. One such source is the nutritional
supplement greens+TM, a blend of several herbal and botanical products containing a substan‐
tial amount of polyphenols including quercetin, apigenin and luteolin [41] which act as
antioxidants and therefore should be able to counteract oxidative stress. Thus, Rao et al [55]
have shown that greens+TM, is more effective in stimulating osteoblasts to form more bone
nodules in a dose-dependant manner than epicatechin, the main polyphenol found in green
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tea. We have further shown that this stimulatory effect is accompanied by decreases in the
reactive oxygen species H2O2 [56].
Two additional nutritional supplements have since been formulated which may prove to be
good for bone health. These are the bone builderTM and the greens+bone builderTM ; the latter
is the original greens+TM product that has been supplemented with the bone builderTM formula
which contains several compounds including vitamins, minerals, and antioxidants. These
various components have been separately shown to have some beneficial effect on bone [57].
Using the human osteoblast SaOS-2 cells, Rao et al showed that similarly to the greens+TM, the
water-soluble bone-builderTM extract had a significant dose-dependent stimulatory effect on
bone nodules formation [58]. It was additionally shown that similarly to the greens+TM, the
watersoluble bone-builderTM extract had a significant dose-dependent stimulatory effect on
bone nodules formation [58]. In a later study, they have shown that when the two supplements,
greens+TM and bone builderTM, were tested as combination, the effects were six times more
effective than either one alone [59]. This led Rao et al to believe that synergistic effects of greens
+TM and bone builderTM may have a beneficial effect on osteoporosis. A product called greens
+bone builderTM is available commercially [57].
A clinical study was then carried out to evaluate the effect of the nutritional supplement greens
+ bone builderTM for 8 weeks on the risk for osteoporosis in postmenopausal women compared
to placebo control [60, 61]. Results have shown that there was an increase in total antioxidant
capacity, as well as a decrease in both lipid and protein oxidation over a 4 and 8-weeks of
intervention with greens+ bone builderTM compared to placebo [60] suggesting that the
nutritional supplement may have a beneficial effect on bone health by mitigating the effects
of oxidative stress. In order to test whether the antioxidant properties of greens+bone build‐
erTM can prevent the risk of osteoporosis in postmenopausal women. Kang et al [60] also
measured the serum bone turnover markers, C-terminal telopeptide of type I collagen (CTX)
as indicator of bone resorption, and procollagen type I N-terminal propeptide (PINP) as
indicator of bone formation and determined their correlations with the serum antioxidant
capacity, and the oxidative stress parameters lipid peroxidation, protein oxidation. Statistical
analysis showed that at 8 weeks, the greens +bone builderTM supplement group significantly
decreased the bone resorption marker CTX, while the Placebo group showed no significant
changes. The supplement group was also significantly different from that of the Placebo group
in all parameters measured. This decrease CTX correlated to the increase in their serum total
antioxidant capacity and decreases in oxidative parameters protein oxidation lipid peroxida‐
tion [61]. These results suggest that a daily supplementation with polyphenols and micronu‐
trients may be important in reducing oxidative damage by reducing bone resorption, thereby
reducing the risk of osteoporosis in postmenopausal women [60, 61].
In summary, studies reported in the literature on the role of polyphenols in bone health have
exploded in the last 10 years, but most of the reports involved in vitro studies in osteoclasts
and osteoblasts, animal studies and epidemiologicai studies. There is little doubt from the
excellent studies reported that oxidative stress is one of the primary culprits responsible for
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the pathogenesis of osteoporosis via its role in osteoclastic resoption and the detrimental effects
on the bone-forming osteoblasts. To date, only four clinical intervention studies have been
reported, including ours. It is easy to see why it is very difficult to evaluate the role of
polyphenols since, as we learned from this review, there are at least 8,000 different polyphenols
identified to date, and each one probably having different effects on humans. Additionally,
polyphenols are present in food with other constituents that may also be beneficial to bone
health. In our clinical study, we combined the effects of a combination of polyphenols present
in the nutritional supplement from greens+TM with the nutritional components present in bone
builderTM such as minerals, vitamins and other nutrients. It is possible that the effects of greens
+bone builderTM in increasing total antioxidant capacity, decreasing the oxidative stress
markers protein oxidation and lipid peroxidation which correlated to the decrease in bone
turnover marker for bone resorption is a result of the combined effects of the different
polyphenols it contained with those of the other nutritional components present in the bone
builderTM. It remained for future studies to zero in on specific component that is responsible
for its beneficial effect.
In conclusion, we showed that oxidative stress due to ROS that are shown to cause the
development of osteoporosis may be prevented by supplementation with the antioxidants
lycopene and polyphenols. Results of in vitro studies in osteoblasts and osteoclasts, animal
intervention studies, epidemiological studies and clinical intervention studies on lycopene and
polyphenols are evidence for their potential use as alternative or complementary agent with
other established drugs approved for the prevention or treatment of osteoporosis in postme‐
nopausal women.
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